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Background: Artemisinin is the major sesquiterpene lactones in sweet wormwood (Artemisia annua L.), and its
combination with transferrin exhibits versatile anti-cancer activities. Their non-selective targeting for cancer cells,
however, limits their application. The aim of this study was to prepare the artemisinin and transferrin-loaded
magnetic nanoliposomes in thermosensitive and non-thermosensitive forms and evaluate their antiproliferative
activity against MCF-7 and MDA-MB-231 cells for better tumor-targeted therapy.
Methods: Artemisinin and transferrin-loaded magnetic nanoliposomes was prepared by extrusion method using
various concentrations of lipids. These formulations were characterized for particle size, zeta potential, polydispersity
index and shape morphology. The artemisinin and transferrin-loading efficiencies were determined using HPLC. The
content of magnetic iron oxide in the nanoliposomes was analysed by spectrophotometry. The in vitro release of
artemisinin, transferrin and magnetic iron oxide from vesicles was assessed by keeping of the nanoliposomes at 37°C
for 12 h. The in vitro cytotoxicity of prepared nanoliposomes was investigated against MCF-7 and MDA-MB-231 cells
using MTT assay.
Results: The entrapment efficiencies of artemisinin, transferrin and magnetic iron oxide in the non-thermosensitive
nanoliposomes were 89.11% ± 0.23, 85.09% ± 0.31 and 78.10% ± 0.24, respectively. Moreover, the thermosensitive
formulation showed a suitable condition for thermal drug release at 42°C and exhibited high antiproliferative activity
against MCF-7 and MDA-MB-231 cells in the presence of a magnetic field.
Conclusions: Our results showed that the thermosensitive artemisinin and transferrin-loaded magnetic nanoliposomes
would be an effective choice for tumor-targeted therapy, due to its suitable stability and high effectiveness.
Keywords: Artemisinin, Transferrin, Liposome, MCF-7 cells, In vitroBackground
Artemisinin is the major sesquiterpene lactones in sweet
wormwood (Artemisia annua L.), and it possesses a
range of medicinal properties including anti-malaria and
anti-cancer activities [1]. This compound has an endo-
peroxide bridge in its structure. When in contact with
high iron concentrations, the molecule releases reactive
oxygen species [2]. It has been documented that cancer
cells need high iron levels to proliferate; hence cancer
cells typically absorb a significantly larger amount of* Correspondence: amirgharib@gmail.com
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unless otherwise stated.transferrin than normal cells and were more susceptible
to artemisinin cytotoxicity [3]. However, the insolubility
of artemisinin in the water and its non-selective tar-
geting towards cancer cells could limit its use [4]. Later
studies demonstrated that the encapsulation of arte-
misinin in drug delivery systems and covalently tagging
artemisinin to transferrin could partly resolve the afore-
mentioned problems, but it could not resolve the spe-
cific targeting of tumors [2,5]. In this case, other options
such as preparing of magnetic nanoliposomes containing
artemisinin and transferrin can be considered.
Magnetic liposomes are spherical and colloidal vesicles
entrapping magnetic iron oxide (Fe3O4) and may range
from tens of nanometers to several micrometers inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Lipid composition of magnetic nanoliposomes
Type of magnetic
nanoliposomes
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iron oxide were used as an important drug delivery sys-
tem, because they can transport drugs to the therapeutic
site for cancer treatment [7]. These carriers could congre-
gate around the magnetic site and act as "intelligent" drug
delivery systems [8]. Moreover, magnetic liposomes have
multi-functionality applications such as image contrasting
in magnetic resonance imaging (MRI) and hyperthermia
cancer therapy [9].
We speculate that encapsulation of artemisinin and
transferrin in magnetic nanoliposomes could increase the
artemisinin and transferrin stability, whilst improving
selective targeting towards cancerous tumors trough mag-
netic attraction and thermosensivity. The ability of co-
encapsulation of artemisinin and transferrin in magnetic
nanoliposomes has not yet been studied. The primary
objective of this study was to prepare the thermosensitive
and non-thermosensitive magnetic nanoliposomes con-
taining artemisinin and transferrin and evaluate their
physicochemical properties. A secondary objective was to
investigate cytotoxicity of prepared nanoliposomes against
MCF-7 and MDA-MB-231 cells using MTTassay.
Methods
Chemicals
Artemisinin (purity ≥ 98%), soy phosphatidylcholine
(SPC), distearoyl phosphatidylcholine (DSPC), dipalmitoyl
phosphatidylcholine (DPPC), cholesterol (CHOL), mag-
netic iron oxide, tamoxifen (an anti-cancer drug, as the
positive control, purity ≥ 99%) and human transferrin
(partially iron saturated, purity ≥ 98%) were obtained from
Sigma (USA). Acetonitrile and ammonium sulphate were
purchased from Merck (Germany). Alpha-modified
Eagle's medium (aMEM) and fetal bovine serum (FBS)
were obtained from Gibco (USA).
Cell culture
MCF-7 (NCBI C135) and MDA-MB-231 (ATCC HTB-26)
breast cancer cell lines were purchased from National Cell
Bank of Iran (Pasteur Institute, Tehran, Iran) and cultured
as described previously [10]. In brief, cells were main-
tained in α-modified Eagle's medium supplemented with
10% FBS, 1% penicillin/streptomycin, 1 mM sodium pyru-
vate and 100 mM non-essential amino acids at 37°C and a
5% CO2 environment.
Preparation of nanoliposomes
To preparation of artemisinin and transferrin-loaded
magnetic nanoliposomes with thermosensitive and non-
thermosensitive properties, the SPC, DSPC, DPPC and
CHOL with different molar ratios (Table 1) were dis-
solved in chloroform and thoroughly dried on a rotary
evaporator (Brinkman, Toronto, Canada) under vacuum
and N2 flow at 30°C. The dried lipids were dispersed byagitation in 6 mL of PBS-ethanol solution (v:v/5:1,
pH = 7.4) containing artemisinin (12 mg), transferrin
(12 mg) and magnetic iron oxide (12 mg) and then
sonicated at 4°C in ultrasonic bath (Braun-sonic 2000,
Burlingame, USA). Finally, artemisinin and transferrin-
loaded magnetic nanoliposomes were obtained by ex-
truding the respective suspension through a polycar-
bonate membrane with 100 nm-sized pores 12 times,
and separating the excess artemisinin, transferrin and
larger lipid aggregation by ultracentrifugation (100000 g,
30 min). Moreover, the non-trapped magnetic iron oxide
was separated by a previously described method [11].
The control magnetic nanoliposomes were prepared
similarly, but PBS (pH, 7.4) was used instead of the arte-
misinin and transferrin solutions. Before the preparation
of nanoliposomes, the phase transition temperatures of
used phospholipids were tested by a differential scanning
calorimetric (DSC) method, as reported previously [12].
Physiochemical characterization of nanoliposomes
Determination of encapsulation efficacy
The content of the artemisinin and transferrin in the
nanoliposomes were determined by HPLC method fol-
lowing dissolution in 0.1% Triton X-100.
To determination of artemisinin, the 20 μL of nanolipo-
somal lysate was injected into the HPLC column. In the
HPLC analysis, a C18 column (3.9 mm× 150 mm, 5 μm,
Waters Co., Milford, USA) and diode array UV detector
was used. The mobile phase was 2:1 (v:v) acetonitrile:
water at a flow rate of 1 mL/min. The calibration curve
was produced by diluting artemisinin stock solution in the
mobile phase. To determination of transferrin, the 25 μL
of nanoliposomal lysate was injected into a Polypropyl A
HPLC column (PolyLC Inc., MD, USA). The column was
eluted with a linear salt gradient from 2 M ammonium
sulfate (pH 6.5) to 0.1 M potassium phosphate (pH 6.5) at
a flow rate of 1 mL/min. The HPLC system was equipped
with UV–vis detector (280 nm). The transferrin calibra-
tion curve was created by diluting its stock solution with
mobile phase.
The content of magnetic iron oxide was determined
using previously reported methods [13], with some
modification. In brief, the magnetic iron oxide nanopar-
ticles were separated using centrifugation after lyses of
nanoliposomes. The precipitate was then dissolved in
0.1 N HCl solution under stirring and a 5 mL of the
supernatant was dissolved in the 750 μL of sulfosalicylic
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of ammonia solution 25% (w/v) was added to the solu-
tion and was analysed by using spectra for the total iron
complex at 425 nm. The absorbance of the diluted sam-
ple obtained from the magnetic iron oxide stock solution
was used for standard curve preparation. Finally, the
percentage of artemisinin, transferrin and magnetic iron
oxide loading were then calculated as:
The amount of artemisinin or transferrin or magnetic
iron oxide in nanoliposome × total volume tested × 100 /
Total sample volume × Initial amount of artemisinin or
transferrin or magnetic iron oxide.
Particle size, zeta-potential and polydispersity index
determination
The mean particle size, zeta-potential and polydispersity
index of the magnetic nanoliposomes were determined using
Malvern zetasizer (Malvern instrument, Worcestershire,
UK) apparatus, as reported previously [14]. Each experi-
ment was done in triplicate.
Shape, surface morphology and magnetic properties
The size and structure of the thermosensitive and non-
thermosensitive magnetic nanoliposomes that contained
artemisinin and transferrin were analysed by cryo-trans-
mission electron microscopy (cryo-TEM), as described
previously [15]. Briefly, a grid was immersed in the nanoli-
posomal sample reservoirs at room temperature, blotted
with blotting paper, drew the sample into the grid and
vitrified in liquid ethane. Subsequently, the sample was
transferred to liquid nitrogen for storage. Digital imaging
was performed at 200 kV in a stage cooled by liquid nitro-
gen. Finally, size analysis was performed using ImageJ soft-
ware (NIH, Bethesda, MD, USA). The magnetic properties
of prepared nanoliposomes were measured using a vibra-
ting sample magnetometer (Meghnatis Daghigh Kavir Co.,
Iran), as described previously [16].
In vitro release study, thermosensitive behaviors and size
stability
To determination of artemisinin, transferrin and magnetic
iron oxide released from the nanoliposomes, a cellulose
membrane (molecular weight cut-off of 8000 kDa, Mem-
brane Filtration Products, USA) was mounted between
the donor and receptor compartments. The donor me-
dium consisted of 1 mL of each magnetic nanoliposomal
formulation. The receptor medium consisted of 10 mL of
citrate-phosphate buffer (0.1 M, pH 7.4). During the dialy-
sis, the temperature was kept at 37°C. At pre-determined
time intervals, between 2 to 12 hours, the amount of the
released artemisinin, transferrin and magnetic iron oxide
were then determined by the above described methods.
To confirm whether the prepared nanoliposomes exhibit a
thermal sensitivity, their stability in 42°C for 4 h wasinvestigated. The size stability of artemisinin and trans-
ferrin-loaded magnetic nanoliposomes was assessed by
measuring the particle sizes after 1 month storage at 4°C.
In vitro efficacy
In vitro selective targeting of MCF-7 and MDA-MB-231
cell lines by prepared magnetic nanoliposomes was per-
formed using previously reported methods [17], with
some modification. Briefly, 100 μL of the MCF-7 and
MDA-MB-231 cells (3 × 104 cells/mL) was added into
each well of a 96-well plate and allowed the cells to at-
tach. In the absence or presence of a magnet, the prolife-
ration of cells in the presence of different concentration
of free and encapsulated artemisinin, transferrin and
magnetic iron oxide for 12, 24, and 48 h was evaluated.
Tamoxifen (7.43 μg/mL) was used as a positive control.
In order to evaluate the antiproliferative effects of free
and encapsulated artemisinin, transferrin and magnetic
iron oxide on MCF-7 and MDA-MB-231 cell lines in the
presence of a magnetic field, a magnet (127.8 × 85.6 ×
7 mm) was added to below the 96-well plate (with 24-
well plate in between), and then the incubation was
done.
At the end of the treatment, cells proliferation was
analysed by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) assay. In brief, 20 μL of
MTT (5 mg/mL in PBS) was added to each well and
samples were incubated for 4 h at 37°C. The MTT solu-
tion was removed, and 200 μL DMSO was added into
each well to dissolve the precipitate. Then, optical den-
sity of the wells was measured at 570 nm.
Data analysis
All data were expressed as means ± standard deviation
(SD). The analysis of variance was performed to deter-
mine the significance level among the tested groups.
The P values less than 0.05 were considered statistically
significant.
Results
The encapsulation efficacies of artemisinin, transferrin and
magnetic iron oxide in the thermosensitive magnetic nano-
liposomes were 83.06% ± 0.53, 80.12% ± 0.12 and 66.14% ±
0.42, respectively. Moreover, the encapsulation efficacies of
artemisinin, transferrin and magnetic iron oxide in the
non-thermosensitive nanoliposomes were 89.11% ± 0.23,
85.09% ± 0.31 and 78.10% ± 0.24, respectively.
Our results showed that the phase transition tem-
perature of DPPC (as the main phospholipid of thermo-
sensitive nanoliposomes) was lower than SPC (Figure 1).
The particle size, zeta-potential and polydispersity index
of the non-thermosensetive nanoliposomes were 99.12 ±
0.11, −1.25 ± 0.23 and 0.21 ± 0.05, respectively. Likewise,
the particle size, zeta-potential and polydispersity index











































Figure 3 Percentages of artemisinin, transferrin and magnetic
iron oxide recoveries for the thermosensitive (A) and
non-thermosensitive (B) magnetic nanoliposomes at 37°C.
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0.15, −1.40 ± 0.22 and 0.19 ± 0.09, respectively.
Cryo-TEM analysis showed that the nanovesicles have
a fine spherical shape and rough surface with a relatively
monodispersed size distribution confirming the size dis-
tribution measurement studies (Figure 2).
The saturation magnetizations for thermosensitive and
non-thermosensitive nanoliposomes were 30.5 and 35.7
electromagnetic unit per gram (emu/g), respectively. In
addition, there was no hysteresis in the magnetization
with both remanence and coercivity, indicating that
these magnetic nanoliposomes were superparamagnetic.
The released amount of artemisinin, transferrin and
magnetic iron oxide at 37°C from each nanoliposomal
formulation were plotted as a function of time (Figure 3).
The percentages of the artemisinin, transferrin and mag-
netic iron oxide recoveries for the thermosensitivity
nanoliposomes after 12 h were 75.3% ± 2.1, 81.5% ± 2.3
and 91.1% ± 1.4, respectively (Figure 3A).
The incubation was conducted at 42°C for 4 h to deter-
mine the extent of spontaneous and nanoliposomal-
mediated artemisinin, transferrin and magnetic iron oxide
released from the prepared nanoliposomes (Figure 4). TheFigure 2 Cryo-transmission electron micrographs of the
thermosensitive (A), and non-thermosensitive (B) magnetic
nanoliposomes loaded with artemisinin and transferrin.results showed an approximately 2-fold increase in arte-
misinin release from thermosensitivity nanoliposomes
after 4 h at 42°C (Figure 4A).
The physical stability of prepared nanoliposomes was
evaluated by comparing different changes in mean diam-
eters during their storage. Two formulations have minor
size changes within 60 days storage at 4°C in PBS, so
that the mean diameter of thermosensitive and non-
thermosensitive nanoliposomes was 98.25 ± 0.14 and
106.20 ± 0.12 nm, respectively.
In the presence or absence of an external magnetic field,
the effect of the combination of artemisinin, transferrin
and magnetic iron oxide in the free and encapsulated
forms on MCF-7 and MDA-MB-231 cellular growth were
examined by MTT assay. The results showed that the cell
proliferation was inhibited in the MCF-7 and MDA-MB-
231 cells in a dose- and time-dependent manner (Figure 5).
Under identical conditions, the viability ratios of treated










































Figure 4 Percentages of artemisinin, transferrin and magnetic
iron oxide recoveries for the thermosensitive (A) and
non-thermosensitive (B) magnetic nanoliposomes at 42°C.
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netic nanoliposomes were more effective than those of
free artemisinin, transferrin and magnetic iron oxide on
MCF-7 and MDA-MB-231 cellular growth. As shown in
Figure 5 C1 and C2, in the presence of magnetic field, the
extent of inhibition increased significantly at 12 h with the
lowest concentration of artemisinin, transferrin and mag-
netic iron oxide in the free and encapsulated forms which
was continued to rise up, with 24 and 48 h durations at
their maximum concentration.
Discussion
The use of plant derived-loaded nanoliposomes for can-
cer therapy has been widely investigated [18,19]. The
main problem associated with the application of such
liposomal formulations is insufficient delivery to the tar-
get site [20]. As an interesting approach to drug delivery
research, magnetic iron oxides were incorporated into
nanoliposomes under the action of a magnetic field
could overcome this limitation [21]. It is documentedthat the magnetic nanoliposomes that contained do-
xorubicin or adriamycin were tailored to target cancer
cells, and the application of a magnetic field could in-
crease drug concentration in the tumors [22,23].
Artemisinin is a sesquiterpene lactone and phytochem-
ical found naturally in Artemisia annua L. [1]. Evidence
for artemisinin’s benefit was strongest for anti-malaria,
anti-oxidative, anti-inflammatory, and anti-cancer effects
[2,5]. It is reported that the anti-cancer effect of artemisi-
nin in the presence of iron sources such as transferrin was
increased several fold [3].
In this study, we evaluated the potential of incorporating
artemisinin and transferrin into magnetic nanoliposomes.
We found that the encapsulation efficiencies of arte-
misinin and transferrin in the thermosensitivity nanolipo-
somes were suitable. According to the literature, this
result was related to some condition, such as liposomal
lipid content [24].
The liposomal particle size is highly dependent on the
molar ratio of membrane lipids [25]. Our results showed
that the increasing of the DPPC molar ratio could reduce
the size of prepared nanoliposomes. Previous researches
showed that the DPPC have excellent biocompatibility to
form small nanoliposomes due to the ratio of head group
size compared to hydrocarbon tail [26].
In this research, we found that the thermosensitive ar-
temisinin and transferrin-loaded magnetic nanolipo-
somes produced a greater reduction in the proliferation
of MCF-7 and MDA-MB-231 cells. This finding is in ac-
cordance with previous studies showing that the size of
magnetic nanoliposomes is an important factor for their
in vitro and in vivo distributions, pharmacodynamics
and effectiveness [27].
The polydispersity index is an important indicator of
the physical stability of nanoliposomes. The polydisper-
sity index values between 0.1 and 0.25 indicate accept-
able uniformity, while values >0.5 are indicative of poor
uniformity [28].
Our results showed that the thermosensitive magnetic
nanoliposomes have an acceptable polydispersity index,
size homogeneity as well as the stability in pH 7.4
citrate-phosphate buffers within 12 h at 37°C. Therefore,
in accordance with previous reports the best prepared
thermosensitive magnetic nanoliposomes not only have
an appropriate particle size and stability for cancer the-
rapy but also have an appropriate size for use as a tar-
geted therapeutic agent [29].
According to the literature, the change in the physico-
chemical properties of nanoparticles could alter their
biokinetics parameters such as their toxicity and bio-
availability [30].
Our study showed that the thermosensitive magnetic
nanoliposomes have a more negative charge than another
formulation. It has been reported that the interactions
Figure 5 Dose- and time-dependent inhibition of MCF-7 and MDA-MB-231 cellular growth by the combined free artemisinin, transferrin and
magnetic iron oxide in the presence of an external magnetic force (A1 and A2), and by the thermosensitive artemisinin and transferrin-loaded
magnetic nanoliposomes without (B1 and B2), and with (C1 and C2) an external magnetic force. (a: Contained 12.50 μg/mL (44.27 μM) artemisinin,
12.80 μg/mL (0.16 μM) transferrin and 9.93 μg/mL (42.88 μM) magnetic iron oxide; b: 2 × a; c: 4 × a; d: 8 × a; e: control magnetic nanoliposones contained
9.93 μg/mL magnetic iron oxide). As a positive control, the tamoxifen (7.43 μg/mL, 20 μM) was used. Data were expressed as mean ± standard deviation
from three independent experiments (*p< 0.05, **p< 0.01 and ***p< 0.001).
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cells such as capillary endothelium are zeta potential de-
pendent [31]. Therefore, it revealed that the thermosensi-
tive magnetic nanoliposomes would have a better potency
for targeted therapy.
We found that the application of an external magnetic
force could increase MCF-7 and MDA-MB-231 cellular
death by artemisinin and transferrin. An approximately
12 h application of magnetic force elicits the maximum
antiproliferation from thermosensitive magnetic nanoli-
posomes, as presently prepared. It was shown that the
in vitro stability of magnetic nanoliposomes could also
affect their performance [32], and our finding could
explain this phenomenon. Magnetic artemisinin and
transferrin-loaded nanoliposomes alone (without mag-
netic force) elicited higher antiproliferative activity on
MCF-7 and MDA-MB-231 cells than free artemisinin,
transferrin and magnetic iron oxide alone or in their
combination. When nanoliposomes containing com-
pounds were used in vitro, they can interact with the
membranes of exposed cancer cells, and therefore de-
crease their viability and proliferation [33]. It is docu-
mented that the effect of the same nanoparticles on
various cells is significantly different and could not be
assumed for other cells [34]. Therefore, in accordance
with "cell vision" effect, we noted that the preparednanoliposomes have antiproliferative effects on the ex-
amined cells, and their efficacy for the other cell types
may be varied.
Conclusion
We have successfully prepared artemisinin and transfer-
rin-loaded magnetic nanoliposomes in the thermosen-
sitive and non-thermosensitive forms with acceptable
uniformity, sustained release profile at 37°C and super-
paramagnetism. Current work demonstrated that arte-
misinin and transferrin-loaded magnetic nanoliposomes,
in particular in the thermosensetive form have potent
anti-growth effect on MCF-7 and MDA-MB-231 cells,
and time-dependently inhibit cell growth in these cell
lines. To the best of our knowledge, artemisinin and
transferrin-loaded magnetic nanoliposomes treatment in
combination with an external magnetic force resulted in
an excellent decrease in proliferation of MCF-7 and
MDA-MB-231 cells. Therefore, these novel formulations
could be a promising approach for artemisinin and
transferrin targeted cancer therapy.
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